טוען...
The effect of locoregional therapies in patients with advanced hepatocellular carcinoma treated with sorafenib
BACKGROUND & AIMS: It is unknown whether the addition of locoregional therapies (LRTx) to sorafenib improves prognosis over sorafenib alone in patients with advanced hepatocellular carcinoma (HCC). The aim of this study was to assess the effect of LRTx in this population. METHODS: A retrospectiv...
שמור ב:
| הוצא לאור ב: | HPB (Oxford) |
|---|---|
| Main Authors: | , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Elsevier
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4857060/ https://ncbi.nlm.nih.gov/pubmed/27154804 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.hpb.2016.02.007 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|